REDW Wealth LLC Buys 60 Shares of Johnson & Johnson (NYSE:JNJ)

REDW Wealth LLC increased its stake in Johnson & Johnson (NYSE:JNJ) by 1.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,442 shares of the company’s stock after buying an additional 60 shares during the quarter. REDW Wealth LLC’s holdings in Johnson & Johnson were worth $566,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of JNJ. OLD Mission Capital LLC bought a new stake in Johnson & Johnson in the third quarter worth $362,000. Centennial Wealth Advisory LLC bought a new stake in Johnson & Johnson in the fourth quarter worth $419,000. Salvus Wealth Management LLC bought a new stake in Johnson & Johnson in the fourth quarter worth $618,000. 4J Wealth Management LLC purchased a new stake in Johnson & Johnson in the fourth quarter worth $340,000. Finally, Westside Investment Management Inc. increased its stake in Johnson & Johnson by 13.6% in the fourth quarter. Westside Investment Management Inc. now owns 5,097 shares of the company’s stock worth $228,775,000 after purchasing an additional 610 shares during the period. Institutional investors own 67.25% of the company’s stock.

Shares of JNJ stock opened at $170.22 on Monday. Johnson & Johnson has a 1-year low of $133.65 and a 1-year high of $173.65. The stock’s 50-day moving average is $164.37 and its 200 day moving average is $157.65. The company has a market cap of $448.26 billion, a P/E ratio of 26.76, a PEG ratio of 3.06 and a beta of 0.70. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.48 and a quick ratio of 1.24.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Monday, April 19th. The company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.34 by $0.25. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The company had revenue of $22.30 billion for the quarter, compared to the consensus estimate of $22 billion. During the same quarter last year, the company earned $2.30 earnings per share. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. On average, analysts anticipate that Johnson & Johnson will post 7.99 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 8th. Shareholders of record on Tuesday, May 25th will be issued a $1.06 dividend. This represents a $4.24 annualized dividend and a yield of 2.49%. The ex-dividend date is Monday, May 24th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.01. Johnson & Johnson’s dividend payout ratio (DPR) is currently 46.54%.

A number of research firms have weighed in on JNJ. SVB Leerink increased their target price on Johnson & Johnson from $180.00 to $200.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 27th. Wells Fargo & Company increased their target price on Johnson & Johnson from $175.00 to $190.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 27th. Raymond James increased their target price on Johnson & Johnson from $158.00 to $183.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 27th. Morgan Stanley increased their target price on Johnson & Johnson from $178.00 to $187.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 27th. Finally, Credit Suisse Group raised their price target on Johnson & Johnson from $168.00 to $193.00 and gave the company an “outperform” rating in a research note on Wednesday, January 27th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. Johnson & Johnson presently has a consensus rating of “Buy” and an average target price of $182.45.

Johnson & Johnson Profile

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Story: How does quantitative easing work?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.